Alopecia Areata Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Date
10/21/2021 6:12:39 PM
(MENAFN- GetNews)
“DelveInsight Business Research LLP” DelveInsight's,“Alopecia Areata – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's “Alopecia Areata Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Alopecia Areata pipeline landscapes. It comprises Alopecia Areata pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alopecia Areata pipeline products.
Some of the key takeaways of the Alopecia Areata Pipeline Report
- Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company/Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, etc., are developing therapies for the treatment of Alopecia Areata.
- Emerging therapies such as PF-06651600, Jaktinib, Baricitinib, ATI-502, LH-8, CTP-543,are expected to have a significant impact on the Alopecia Areata market in the coming years.
Get an overview of pipeline landscape @ Alopecia Areata Clinical Trials Analysis
Alopecia Areata Overview
Alopecia Areata (AA) is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times on other areas of the body. The affected hair follicles are attacked by a person's immune system (white blood cells), which results in the seizing of the hair growth stage. Hair follicles remain alive, and hair can regrow at any time in Alopecia Areata. Alopecia Areata usually begins with one or more patches which may be small, round, smooth on the scalp that can progress to total scalp hair loss or complete body hair loss. Genetic predisposition and environmental factors increase the chances of developing Alopecia Areata.
Alopecia Areata Emerging Drugs
PF-06651600: Pfizer Jaktinib: Suzhou Zelgen Biopharmaceuticals Baricitinib: Eli Lilly and Company/Incyte Corporation ATI-502: Alcaris Therapeutics LH-8: Legacy Healthcare CTP-543: Concert Pharmaceuticals For further information, refer to the detailed report @ Alopecia Areata Pipeline Therapeutics
Scope of Alopecia Areata Pipeline Drug Insight
- Coverage: Global
- Major Players: Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company/Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, and others.
- Pipeline Therapies: PF-06651600, Jaktinib, Baricitinib, ATI-502, LH-8, CTP-543, and others.
Table of Contents
| 1 | Alopecia Areata Report Introduction |
| 2 | Alopecia Areata Executive Summary |
| 3 | Alopecia Areata Overview |
| 4 | Alopecia Areata- Analytical Perspective In-depth Commercial Assessment |
| 5 | Alopecia Areata Pipeline Therapeutics |
| 6 | Alopecia Areata Late Stage Products (Phase II/III) |
| 7 | Alopecia Areata Mid Stage Products (Phase II) |
| 8 | Alopecia Areata Early Stage Products (Phase I) |
| 9 | Alopecia Areata Preclinical Stage Products |
| 10 | Alopecia Areata Therapeutic Assessment |
| 11 | Alopecia Areata Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Alopecia Areata Key Companies |
| 14 | Alopecia Areata Key Products |
| 15 | Alopecia Areata Unmet Needs |
| 16 | Alopecia Areata Market Drivers and Barriers |
| 17 | Alopecia Areata Future Perspectives and Conclusion |
| 18 | Alopecia Areata Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Get a customized pipeline report @ Alopecia Areata Drugs Pipeline Report
MENAFN21102021003238003268ID1103016927
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.